Ascendis Pharma A/S

Catalyst AI-extracted

YUVIWEL

achondroplasia with open epiphyses

Resolved

97days ago

Catalyst readout · Apr 1, 2026

What's at stake A key catalyst for YUVIWEL (achondroplasia with open epiphyses) is expected Apr 1, 2026.

Primary source · SEC 6-K verified 13h ago

“Phase 3 trial planned to investigate TransCon CNP monotherapy for the treatment of hypochondroplasia in the second half of the year.”

5 sources on file.

Link copied ✓